date:Jan 17, 2019
. Last month, the company secured a US$34m investment from the European Investment Bank (EIB) to increase and accelerate its use of AI to improve global healthcare.
The investment followed Nuritas launch of PeptAIde earlier in 2018, in cooperation with BASF, which demonstrated how AI can accelerate the discovery of healthcare products. Future investment from EIB is to scale up development of new therapeutics in areas of interest including anti-aging, anti-inflammatory and diabetes treatment.